Why is Concord Drugs falling/rising?

As of 04-Jul, Concord Drugs Ltd is experiencing a decline in its stock price, currently at Rs 50.28, which represents a decrease of 3.01 (-5.65%). The stock has recently hit a new 52-week high of Rs 56.8 but has fallen after six consecutive days of gains, indicating a trend reversal. The stock's performance today has underperformed its sector by 6.16%, with a wide intraday trading range of Rs 7.55, reflecting high volatility. Despite a strong year-to-date return of 32.32% and a significant rise of 60.64% over the past month, the company's profits have decreased by 13% over the last year, which may be contributing to the current price drop. Additionally, while the stock is trading at a discount compared to its peers, its weak long-term fundamental strength, including a -4.49% CAGR growth in operating profits over the last five years, raises concerns among investors.
In the broader market context, Concord Drugs has outperformed the Sensex in both the short-term and long-term, with a 39.67% return over the past week compared to a slight decline of 0.74% in the benchmark index. However, the stock's recent underperformance today may reflect investor caution due to its declining profitability and weak ability to service debt, as indicated by a poor EBIT to Interest ratio. This combination of strong historical performance and current financial challenges may be leading to a reassessment of the stock's value, contributing to its price decline despite its previous gains.